Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,283 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 Trial Evaluating Minocycline for Geographic Atrophy in Age-Related Macular Degeneration: A Nonrandomized Controlled Trial.
Keenan TDL, Bailey C, Abraham M, Orndahl C, Menezes S, Bellur S, Arunachalam T, Kangale-Whitney C, Srinivas S, Karamat A, Nittala M, Cunningham D, Jeffrey BG, Wiley HE, Thavikulwat AT, Sadda S, Cukras CA, Chew EY, Wong WT. Keenan TDL, et al. Among authors: bailey c. JAMA Ophthalmol. 2024 Apr 1;142(4):345-355. doi: 10.1001/jamaophthalmol.2024.0118. JAMA Ophthalmol. 2024. PMID: 38483382 Clinical Trial.
Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice.
Guymer R, Bailey C, Chaikitmongkol V, Chakravarthy U, Chaudhary V, Finger RP, Gallego-Pinazo R, Chuan AKH, Ishida S, Lövestam-Adrian M, Parravano M, Luna Pinto JD, Schmitz-Valckenberg S, Sheth V, Souied EH, Chi GC, Gilberg F, Glittenberg C, Scheidl S, Bengus M. Guymer R, et al. Among authors: bailey c. Ophthalmol Sci. 2023 Dec 3;4(3):100442. doi: 10.1016/j.xops.2023.100442. eCollection 2024 May-Jun. Ophthalmol Sci. 2023. PMID: 38304609 Free PMC article.
XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration.
Korobelnik JF, Chaudhary V, Mitchell P, Kang SW, Tadayoni R, Allmeier H, Lee J, Zhang X, Machewitz T, Bailey C. Korobelnik JF, et al. Among authors: bailey c. Ophthalmol Ther. 2024 Mar;13(3):725-738. doi: 10.1007/s40123-023-00867-x. Epub 2024 Jan 10. Ophthalmol Ther. 2024. PMID: 38198053 Free PMC article.
Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of Aflibercept.
Narendran N, Bailey C, Downey L, Gale R, Kotagiri A, Pearce I, Rennie CA, Sivaprasad S, Talks J, Morgan-Warren P, Napier J, O'Neil C, Seeborne T. Narendran N, et al. Among authors: bailey c. Clin Ophthalmol. 2024 Nov 2;18:3133-3142. doi: 10.2147/OPTH.S481772. eCollection 2024. Clin Ophthalmol. 2024. PMID: 39512482 Free PMC article.
Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, Gerstner O, Bouazza AS, Shen H, Osborne A, Mitchell P; RESTORE Extension Study Group. Schmidt-Erfurth U, et al. Ophthalmology. 2014 May;121(5):1045-53. doi: 10.1016/j.ophtha.2013.11.041. Epub 2014 Feb 1. Ophthalmology. 2014. PMID: 24491642 Free article. Clinical Trial.
3,283 results